The Warburg effect: From theory to therapeutic applications in cancer;L'effet Warburg: De la théorie du cancer aux applications thérapeutiques en cancérologie

Medecine/Sciences

Volumn 29, Issue 11, 2013, Pages 1026-1033

  Razungles, Julie ^a   Cavaillès, Vincent ^a   Jalaguier, Stéphan ^a   Teyssier, Catherine ^a  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ANIMAL; ART; CARCINOGENESIS; CELL PROLIFERATION; CELLS; ENERGY METABOLISM; GENETICS; GERMANY; GLYCOLYSIS; HISTORY; HUMAN; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION; THEORETICAL MODEL;

ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; CELLS; ENERGY METABOLISM; GERMANY; GLUCOSE; GLYCOLYSIS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; MODELS, THEORETICAL; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84889641421     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20132911020     Document Type: Review

References (43)

1. Warburg, O. On the origin of cancer cells. Science 1956; 123: 309-314.
2. Ward, PS; Thompson, CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012; 21: 297-308.
3. Dang, CV. Links between metabolism and cancer. Genes Dev 2012; 26: 877-890.
4. Vander Heiden, MG; Cantley, LC; Thompson, CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
5. Wolf, A; Agnihotri, S; Micallef, J; et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiform. J Exp Med 2011; 208: 313-326.
6. Gottlob, K; Majewski, N; Kennedy, S; et al. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001; 15: 1406-1418. (Pubitemid 32524647)
7. Chesney, J; Mitchell, R; Benigni, F; et al. An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci USA 1999; 96: 3047-3052. (Pubitemid 29148841)
8. Christofk, HR; Vander Heiden, MG; Harris, MH; et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233. (Pubitemid 351380249)
9. David, CJ; Chen, M; Assanah, M; et al. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463: 364-368.
10. Wang, Z; Jeon, HY; Rigo, F; et al. Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides. Open Biol 2012; 2: 120133.
11. Elstrom, RL; Bauer, DE; Buzzai, M; et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64: 3892-3899. (Pubitemid 38697301)
12. Robey, RB; Hay, N. Is Akt the Warburg kinase? Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 2009; 19: 25-31.
13. Wofford, JA; Wieman, HL; Jacobs, SR; et al. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood 2008; 111: 2101-2111. (Pubitemid 351451522)
14. Chiaradonna, F; Sacco, E; Manzoni, R; et al. Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 2006; 25: 5391-404. (Pubitemid 44330282)
15. Yun, J; Rago, C; Cheong, I; et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325: 1555-1559.
16. Faubert, B; Boily, G; Izreig, S; et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013; 17: 113-124.
17. Brahimi-Horn, C; Pouyssegur, J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 2006; 93: E73-E80.
18. Lu, H; Forbes, RA; Verma, A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002; 277: 23111-23115. (Pubitemid 34952134)
19. Dang, CV; Le, A; Gao, P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15: 6479-6483.
20. Yuneva, M; Zamboni, N; Oefner, P; et al. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007; 178: 93-105. (Pubitemid 47026405)
21. Shen, L; Sun, X; Fu, Z; et al. The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy. Clin Cancer Res 2012; 18: 1561-1567.
22. Bensaad, K; Tsuruta, A; Selak, MA; et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-120. (Pubitemid 44040989)
23. Schwartzenberg-Bar-Yoseph, F; Armoni, M; Karnieli, E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004; 64: 2627-2633. (Pubitemid 38523921)
24. Kawauchi, K; Araki, K; Tobiume, K; et al. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008; 10: 611-618. (Pubitemid 351627381)
25. Matoba, S; Kang, JG; Patino, WD; et al. p53 regulates mitochondrial respiration. Science 2006; 312: 1650-1653. (Pubitemid 43902663)
26. Contractor, T; Harris, CR. p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res 2012; 72: 560-567.
27. Lagarrigue, S; Blanchet, E; Annicotte, JS; et al. Le double jeu des régulateurs du cycle cellulaire. Med Sci (Paris) 2011; 27: 508-513.
28. Chen, HZ; Tsai, SY. Leone G Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9: 785-797.
29. Hsieh, MC; Das, D; Sambandam, N; et al. Regulation of the PDK4 isozyme by the Rb-E2F1 complex. J Biol Chem 2008; 283: 27410-27417.
30. Cai, Q; Lin, T; Kamarajugadda, S; et al. Regulation of glycolysis and the Warburg effect by estrogen-related receptors. Oncogene 2013; 32: 2079-2086.
31. Gao, P; Sun, L; He, X; et al. MicroRNAs and the Warburg effect: new players in an old arena. Curr Gene Ther 2012; 12: 285-291.
32. Eichner, LJ; Perry, MC; Dufour, CR; et al. miR-378 mediates metabolic shift in breast cancer cells via the PGC-1beta/ERRgamma transcriptional pathway. Cell Metab 2010; 12: 352-361.
33. Gatenby, RA; Gillies, RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-899. (Pubitemid 39472955)
34. Terret, C; Solari, F. L-homéostasie métabolique au cœur du vieillissement. Med Sci (Paris) 2012; 28: 311-315.
35. Vander Heiden MG Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011; 10: 671-684.
36. Foretz, M; Viollet, B. Mécanisme d-inhibition de la production hépatique de glucose par la metformine. Med Sci (Paris) 2010; 26: 663-666.
37. Tong, X; Zhao, F; Thompson, CB. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 2009; 19: 32-37.
38. Kuhajda, FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000; 16: 202-208. (Pubitemid 30114274)
39. Yang, W; Xia, Y; Ji, H; et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011; 480: 118-122.
40. Lu, C; Thompson, CB. Metabolic regulation of epigenetics. Cell Metab 2012; 16: 9-17.
41. Sebastian, C; Zwaans, BM; Silberman, DM; et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 2012; 151: 1185-1199.
42. Foretz, M; Taleux, N; Guigas, B; et al. Régulation du métabolisme par l-AMPK: une nouvelle voie thérapeutique pour le traitement des maladies métaboliques et cardiaques. Med Sci (Paris) 2006; 22: 381-388.
43. Foretz, M; Viollet, B. Les nouvelles promesses de la metformine: vers une meilleure compréhension de ses mécanismes d-action. Med Sci (Paris) 2013; 29 (sous presse).